.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The STEP 1 trial assessed once-weekly semaglutide 2.4 mg plus lifestyle intervention in adults with overweight or obesity without diabetes. After 68 weeks, average body-weight reduction was substantially greater with semaglutide than with placebo, and a greater proportion of treated participants achieved clinically meaningful weight-loss thresholds. Improvements were also seen in cardiometabolic measures and physical-function-related outcomes. The study is relevant to internal medicine because effective obesity treatment can influence hypertension, dysglycemia, lipids and broader cardiovascular risk. However, it also highlights the chronic nature of pharmacologic weight management: after treatment discontinuation, substantial weight regain can occur, emphasizing the need for long-term management rather than short courses. For physicians, the practical approach includes assessing obesity-related complications, setting realistic weight goals, monitoring gastrointestinal tolerability and reinforcing behavioral support. Drug therapy should complement—not replace—nutritional and activity interventions. STEP 1 helped establish modern anti-obesity pharmacotherapy as a legitimate part of comprehensive chronic disease care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The STEP 1 trial assessed once-weekly semaglutide 2.4 mg plus lifestyle intervention in adults with overweight or obesity without diabetes. After 68 weeks, average body-weight reduction was substantially greater with semaglutide than with placebo, and a greater proportion of treated participants achieved clinically meaningful weight-loss thresholds. Improvements were also seen in cardiometabolic measures and physical-function-related outcomes. The study is relevant to internal medicine because effective obesity treatment can influence hypertension, dysglycemia, lipids and broader cardiovascular risk. However, it also highlights the chronic nature of pharmacologic weight management: after treatment discontinuation, substantial weight regain can occur, emphasizing the need for long-term management rather than short courses. For physicians, the practical approach includes assessing obesity-related complications, setting realistic weight goals, monitoring gastrointestinal tolerability and reinforcing behavioral support. Drug therapy should complement—not replace—nutritional and activity interventions. STEP 1 helped establish modern anti-obesity pharmacotherapy as a legitimate part of comprehensive chronic disease care.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
